You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mismatch Repair

Showing 1 - 25 of 4,517
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MSI-H Colorectal Cancer Trial (colorectal resection)

Completed
  • MSI-H Colorectal Cancer
  • colorectal resection
  • (no location specified)
May 22, 2023

Endometrial Tumors, Endometrial Cancer Trial in Seoul (Nivolumab)

Not yet recruiting
  • Endometrial Neoplasms
  • Endometrial Cancer
  • Seoul, Korea, Republic of
    Severance Hospital, Yonsei University Health System
Mar 21, 2023

MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers Trial in Kashiwa (HRO761,

Recruiting
  • MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
  • Kashiwa, Chiba, Japan
    Novartis Investigative Site
May 2, 2023

Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair Trial in China (S1,

Not yet recruiting
  • Adenocarcinoma of the Stomach
  • +2 more
  • Hangzhou, Zhejiang, China
  • +4 more
May 23, 2023

Recurrent Endometrial Cancer, Solid Tumors Trial in Pittsburgh (pembrolizumab, Sitravatinib)

Recruiting
  • Recurrent Endometrial Cancer
  • Solid Tumors
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 12, 2022

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer Trial in Houston (Tecentriq 1200 MG in 20 ML Injection +

Not yet recruiting
  • Stage I Colon Cancer
  • +2 more
  • Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2
  • +2 more
  • Houston, Texas
    Baylor College of Medicine
May 22, 2023

Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

Active, not recruiting
Has Results
  • Colorectal Carcinoma
  • (no location specified)
Oct 28, 2022

Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

Active, not recruiting
  • Colorectal Cancer
  • IBI310 (anti-CTLA-4 antibody)
  • Sintilimab(anti-PD-1 antibody)
  • Beijing, China
    Beijing cancer hospital
Sep 15, 2022

Endometrial Cancer, Mismatch Repair-Proficient, Recurrent Endometrial Cancer Trial in Richmond (Lenvatinib, Pembrolizumab)

Recruiting
  • Endometrial Cancer
  • +2 more
  • Richmond, Virginia
    Virginia Commonwealth University
Apr 5, 2022

Epstein-Barr Virus Positive, Gastric Adenocarcinoma, Mismatch Repair Protein Deficiency Trial in New Brunswick (drug, other,

Recruiting
  • Epstein-Barr Virus Positive
  • +10 more
  • Atlanta, Georgia
  • +2 more
Dec 10, 2022

Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

Not yet recruiting
  • Adenocarcinoma - GEJ
  • Gastric Adenocarcinoma
  • (no location specified)
Sep 26, 2023

Anal Squamous Cell Carcinoma, Colorectal Tumors, Soft Tissue Sarcoma Trial (Regorafenib in combination with Tislelizumab)

Not yet recruiting
  • Anal Squamous Cell Carcinoma
  • +7 more
  • Regorafenib in combination with Tislelizumab
  • (no location specified)
Oct 12, 2022

Locally Advanced Malignant Solid Tumor Trial in Houston (Pembrolizumab)

Recruiting
  • Locally Advanced Malignant Solid Neoplasm
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Mar 22, 2022

Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

Not yet recruiting
  • Colorectal Cancer Stage IV
  • +2 more
  • (no location specified)
Jun 19, 2022

Colon Cancer, DMMR Colorectal Cancer Trial (Dostarlimab)

Not yet recruiting
  • Colon Cancer
  • DMMR Colorectal Cancer
  • (no location specified)
Feb 4, 2022

Registry Study in MSI/dMMR Solid Tumors

Not yet recruiting
  • DMMR Cancer
  • +2 more
    • (no location specified)
    Aug 21, 2023

    Endometrial Cancer Trial (Anlotinib + Camrelizumab)

    Not yet recruiting
    • Endometrial Cancer
    • Anlotinib + Camrelizumab
    • (no location specified)
    Sep 26, 2022

    DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

    Not yet recruiting
    • Endometrial Cancer
    • (no location specified)
    Feb 14, 2023

    Colorectal Cancer, Liver Metastases, MSS Trial (Sinti+Rego+Cele)

    Not yet recruiting
    • Colorectal Cancer
    • +2 more
    • (no location specified)
    Jul 3, 2023

    Advanced Solid Tumors Trial (RO7589831)

    Not yet recruiting
    • Advanced Solid Tumors
    • (no location specified)
    Aug 16, 2023

    Locally Advanced Rectal Cancer Trial in Guangzhou (AK104, Capecitabine, Neoadjuvant Radiotherapy)

    Not yet recruiting
    • Locally Advanced Rectal Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Aug 5, 2023

    Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma Trial in Houston

    Active, not recruiting
    • Advanced Colorectal Carcinoma
    • +24 more
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 20, 2022

    Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC) Trial (INCB 99280 with Ipilimumab)

    Not yet recruiting
    • Melanoma
    • +5 more
    • INCB 99280 with Ipilimumab
    • (no location specified)
    Jun 9, 2023

    Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors Trial in Baltimore (Nivolumab, Relatlimab)

    Recruiting
    • Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
    • MSI-H Tumors
    • Baltimore, Maryland
      Sidney Kimmel Comprehensive Cancer Center
    Mar 14, 2022